Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

Breadcrumb trail:

Medical Oncology Board

Expand All | Collapse All

Robert D. Siegel, MD, Chair

Robert D. Siegel, MDDr. Siegel, a board certified internist, hematologist and medical oncologist, is the Oncology Program Director for the Bon Secours St. Francis Health System in Greenville, South Carolina. Prior to his appointment to program leadership at St. Francis, Dr. Siegel had been a community-based oncologist with particular interest in quality improvement initiatives and cancer care delivery research.

Dr. Siegel has served the American Board of Internal Medicine (ABIM) as a member of the Medical Oncology Exam Writing Committee and is currently chair of its Medical Oncology Board. Additionally, he is a member of the ABIM Board of Directors and the ABIM Council. He has previously served as the co-Chair of the Quality of Care Subcommittee for the National Cancer Institute's Community Cancer Centers Program and is currently on the Executive Committee of the Upstate Carolina NCI Community Oncology Research program (NCORP).

Dr. Siegel earned his medical degree at the Columbia University College of Physicians and Surgeons in New York. He completed his internship and residency training at the Barnes Hospital/Washington University School of Medicine in St. Louis and fellowship training in medical oncology and hematology at the Dana-Farber Cancer Institute and Harvard Medical School in Boston.

As of July 2019, Dr. Siegel reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Bon Secours St. Francis Hospital, from the following companies:

  • Bristol-Myers Squibb, for a lung cancer clinical trial, kidney cancer clinical trial, and for a non-Hodgkin lymphoma clinical trial.
  • Cancer Insight, for a melanoma clinical trial.
  • Merck, for clinical trials for head and neck carcinoma, breast carcinoma, lymphoma, and stomach cancer clinical trials.
  • Mirati Therapeutics, for a clinical trial for solid tumors.
  • Biodesix, for an observational study assessing the clinical effectiveness of validating immunotherapy tests in subject with non-small cell lung cancer.
  • CerRX Inc., for a Phase II trial of intravenous fenretinide emulsion for patients with relapsed/refractory peripheral T-cell lymphomas.
  • Boston Biomedical, for a Phase II trial of metastatic pancreatic ductal adenocarcinoma.
  • GRAIL, Inc., for a trial of use deep sequencing of circulating cell-free nucleic acids to develop assays to detect cancer early in blood.
  • Pharmatech, for a trial of the treatment of cutaneous T-cell lymphoma.

Dr. Siegel serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society for Clinical Oncology, Past Chair of Quality Oncology Practice Initiative Certification Oversight Committee, Chair Elect Quality Oncology Practice Initiative Steering Group, Quality Care Committee Member, and International Quality Task Force Member, receiving reimbursement for travel expenses.
  • Guardian Research Network, Board of Directors, without compensation. Southeastern Health Partners, Board of Managers, without compensation.

Dr. Siegel also reported speaking to the North and South Carolina Oncology Societies on MOC in 2019.

Linda S. Ahn, MSN

Linda S. Ahn, MSNMs. Ahn is a Clinical Trials Nurse Practitioner in the Thoracic Medicine Program at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. She has worked at MSKCC for 14 years, starting as a new graduate RN on the Genitourinary/Head &Neck inpatient service. She then worked as an office practice nurse in the Gastrointestinal/Sarcoma program in the outpatient setting.

After receiving a master's degree in Adult Primary Care in 2008, she took a position as a Clinical Trials Nurse Practitioner in the Sarcoma Program. She briefly left MSKCC for a position as Nurse Practitioner overseeing sarcoma patients in the outpatient setting at Mount Sinai Hospital in New York City.

Currently, she is a member of Oncology Nursing Society and American Society of Clinical Oncology, she also a member of the American Board of Internal Medicine Medical Oncology Board. She is board certified as an Adult Nurse Practitioner and is certified as an Advanced Oncology Certified Nurse Practitioner. Ms. Ahn earned her bachelor's degree in nursing from SUNY Binghamton and master's degree in Adult Primary Care from New York University.

As of June 2019, Ms. Ahn reported no external relationships:

Tareq Al Baghdadi, MD

Dr. Al Baghdadi is a practicing board certified hematologist and medical oncologist at IHA Hematology and Oncology Associates in Ypsilanti, Michigan. He is also affiliated with St. Joseph Mercy Ann Arbor in Ann Arbor, Michigan.

Dr. Al Baghdadi has clinical interest in hematology, and breast and urologic cancers. He is a member of the American Board of Internal Medicine Medical Oncology Board, the National Cancer Institute Leukemia Steering Committee and the National Myelodysplastic Syndromes Study Steering Committee. Dr. Al Baghdadi also serves as co-Principal Investigator for the Michigan Cancer Research Consortium and is a member of the Alliance Community Oncology Leadership Committee.

Dr. Al Baghdadi is a member of the ASCO TAPUR Molecular Tumor Board, and also a member of the Alliance GU Oncology committee and has completed ASCO leadership training program.

He received his medical degree from the University of Damascus Faculty of Medicine in Syria. He completed residency training at William Beaumont Hospital in Royal Oak, Michigan, and fellowship training in hematology and oncology at Indiana University in Indianapolis, Indiana.

As of April 2019, Dr. Al Baghdadi reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Bristol-Myers Squibb
  • Cardinal Health
  • Celgene

Ann S. LaCasce, MD

Ann S. LaCasce, MDDr. LaCasce graduated from Bowdoin College with a degree in Biochemistry and earned her medical degree from Tufts University School of Medicine. She completed training in internal medicine at Brigham and Women's Hospital in Boston, where she later served as a Chief Medical Resident. After her fellowship in medical oncology at Dana-Farber/Partners Cancer Care where she pursued formal training in clinical investigation, earning a Master in Medical Science from Harvard/MIT Division of Health Sciences and Technology. Since 2003, she has been a member of the Lymphoma Program at Dana-Farber where she performs clinical research.

She has a longstanding interest in medical education, and in 2011, she assumed the role of Program Director of the Dana-Farber/Partners Cancer Care Fellowship which is the largest hematology/oncology training program in the country. She is an Associate Professor of Medicine at Harvard Medical School and is board certified in medical oncology.

She serves as a member of the American Board of Internal Medicine Medical Oncology Board; and she also serves as a member of the American Society of Hematology Committee on Training and is chair, American Society of Clinical Oncology Training Program Committee. In addition, she is a member of the National Comprehensive Cancer Network's Lymphoma Guideline Panel and serves on the Lymphoma Research Foundation's Scientific Advisory Board.

As of June 2019, Dr. LaCasce reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with and honoraria:

  • Bristol-Myers Squibb.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

  • Seattle Genetics.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Research to Practice, for a lymphoma panel.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for authorship.

Suresh G. Nair, MD

Suresh G. Nair, MDSuresh Nair, MD, is the Physician-in-Chief of the Lehigh Valley Cancer Institute and leads the health network’s academic programs. Dr. Nair is the Medical Director of the Lehigh Valley Cancer Institute membership in the Memorial Sloan Kettering Cancer Center Alliance and has practiced oncology in the community setting for 30 years. He is the initial holder of The Auxiliary of Lehigh Valley Hospital Endowed Chair in Cancer.

With clinical expertise in melanoma, kidney cancer and immunotherapy, Dr. Nair’s focus is to provide the highest-quality cancer care, including standard and research treatments. He leads a variety of clinical trials at Lehigh Valley Health Network (LVHN) to provide leading-edge options to patients. Dr. Nair started the hematology/oncology fellowship at LVHN and served as the initial program director, and remains on core faculty. He is a member of the American Board of Internal Medicine Medical Oncology Board.

Dr. Nair has been a site principal investigator in the National Cancer Institute (NCI) Cooperative Group Program for over 25 years and was the first Chair of the NCI Early Phase Central IRB. He has been a site principal investigator of over 40 T-cell checkpoint inhibitor trials at the Lehigh Valley Cancer Institute.

Dr. Nair received his medical degree from Jefferson Medical College. He completed his residency at Geisinger Medical Center and his fellowship at the University of Pittsburgh.

As of May 2018, Dr. Nair reported the following external relationships:

Funding for clinical trial support accrual, paid to Lehigh Valley Health Network, from the following companies:

  • Bristol-Myers Squibb, for Phase II and Phase III Immuno-Oncology clinical trials.
  • Merck, for a Phase III clinical trial for treatment of metastatic renal carcinoma.
  • DNAtrix, for a Phase II clinical trial for treatment of glioblastoma.

Olatoyosi Odenike, MD

Dr. Odenike, a board certified medical oncologist, is an Associate Professor of Medicine at the University of Chicago. Dr. Odenike's clinical research and medical practice is focused on myeloid malignancies, including acute and chronic leukemias, myelodysplastic syndromes and chronic myeloproliferative neoplasms. She has a particular interest in new drug development in these diseases.

Prior to joining the faculty at the University of Chicago, Dr. Odenike worked as an Attending Physician at Roseland Community hospital, a medically underserved community on the South Side of Chicago.

Dr. Odenike currently serves as member of the American Board of Internal Medicine Medical Oncology Board Exam Committee and Medical Oncology Specialty Board. She is co-Director of the University of Chicago Phase II Consortium and is a member of the Alliance Leukemia Core Committee. Additionally, she has served on various professional committees including American Society of Clinical Oncology (ASCO) Scientific Program Committee for which she also served as a Track Leader, ASCO Cancer Communications Committee and the Best of ASCO Program Committee, and she has served as Chair of Educational Programs for both ASCO and the American Society of Hematology (ASH). She is also a member of the ASH Consult a Colleague Program. She has served in various editorial capacities and review committees including the Conquer Cancer Foundation of ASCO grant review committee, ASCO International Innovation Grant review subcommittee and currently serves as Vice Chair of the Aplastic Anemia/MDS International Foundation Medical Advisory Board. In addition, Dr. Odenike has served on the Molecular and Cellular Hematology National Institutes of Health Study Section. She is the recipient of an ASCO Career Development Award and is listed in Best Doctors in America as well as Castle Connolly's Top Doctors.

Dr. Odenike received her pre-medical training at the University of Ife, Nigeria, and her medical degree from the University of Ibadan, Nigeria. She completed her residency training in internal medicine and pediatrics at the University of Illinois and her fellowship training in hematology/oncology at the University of Chicago.

As of May 2019, Dr. Odenike reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following companies:

  • Astex Pharmaceuticals, receiving funding for a Phase I/II study on patients with myelodysplastic syndromes.
  • Gilead Sciences, receiving funding for a Phase III study on patients with bone marrow disorders.
  • MEI Pharma, receiving funding for a Phase II study on patients with newly diagnosed acute myeloid leukemia.
  • NS Pharma, receiving funding for a Phase I/II trial of patients with bone marrow disorders.

Karen L. Reckamp, MD

Dr. Reckamp is board certified in Hematology and Medical Oncology and is Associate Professor of Medicine in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center in Duarte, California. The focus of her academic career includes developing and evaluating novel therapies for lung cancer as the Medical Director of the Thoracic Oncology Program at City of Hope. She serves as Chair of the Scientific Review Committee for the City of Hope Comprehensive Cancer Center.

Dr. Reckamp serves as a member of the American Board of Internal Medicine (ABIM) Medical Oncology Board. She also participates on the Scientific Advisory Board for the Free to Breathe foundation. She is a member of the American Society of Clinical Oncology (ASCO) Professional Development Committee. She was selected as a participant in the ASCO Leadership Development Program, which led a project on Maintenance of Certification in medical oncology. She previously participated in ASCO Test Material Development with instruction from ABIM.

Dr. Reckamp earned her medical degree from University of Chicago Pritzker School of Medicine and her master's degree in clinical investigation through the Specialized Training in Advanced Research from the Department of Biomathematics at University of California, Los Angeles (UCLA). Her postgraduate training includes an internship and residency in internal medicine at Barnes-Jewish Hospital in St. Louis, Missouri, and a hematology/oncology fellowship at the David Geffen School of Medicine at UCLA.

As of April 2019, Dr. Reckamp reported the following external relationships:

Clinical research, with funding for clinical trial expenses and clinical research staff, paid directly to City of Hope Cancer Center from the following companies:

  • Acea, to support a Phase I trial of epidermal growth factor receptor in non-small cell lung cancer.
  • Adaptimune, to support a trial on NY-ESO and MAGE-A10 CART cells.
  • Gilead Sciences, to support a Phase I trial of momelotinib and erlotinib.
  • Genentech, to support a trial of atezolizumab.
  • Takeda, to support a Phase II trial of AP26113.
  • Boerhinger Ingelheim, to support a trial of afatinib in older adults.
  • Bristol-Myers Squibb, to support a Phase I trial with combination IO; Phase II trial with immunotherapy combinations in lung cancer.
  • Janssen, to support a Phase I trial.
  • Loxo, to support a Phase I trial of Loxo-292 in RET-altered cancers.
  • Seattle Genetics, to support a Phase I trial of SGN-2FF.
  • Xcovery, to support a Phase I/II trial of ensartinib in ALK non-small cell lung cancer.
  • Zeno, to support a Phase I trial of Zn in EGFR non-small cell lung cancer.

Service on data and safety monitoring boards for the following companies, with compensation as listed:

Genentech, for a Phase III trial of neoadjuvant atezolizumab, receiving reimbursement for travel expenses and honoraria. Tesaro, for Phase II immunotherapy combination trials, receiving honoraria.Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation for travel expenses and/or honoraria:

  • AstraZeneca, consulting on osimertinib and durvalumab, receiving reimbursement for travel expenses and honoraria.
  • Exelixis, consulting on cabozantinib, receiving honoraria.
  • Guardant Health, consulting on liquid biopsy testing, receiving honoraria.
  • Loxo, consulting for larotrectinib and Loxo-292, receiving honoraria.
  • Precision health, consulting for patient outcomes, receiving honoraria.
  • Takeda, consulting on brigatinib, receiving reimbursement for travel expenses and honoraria.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Clinical Care Options, education on treatment for lung cancer.
  • PER, education on treatment for lung cancer.
  • Axis, education on treatment for lung cancer and mentoring oncologists in-training.

Dr. Reckamp serves in significant roles with the following healthcare-related organization, receiving reimbursement or compensation as listed:

  • American Society for Clinical Oncology, Quality of Care Committee, receiving travel reimbursement.
  • National Comprehensive Cancer Network, Lung Cancer Guideline Committee and Advisor for lung cancer educational material, Arizona Requests for Proposal Committee Member, receiving travel reimbursement and consulting fees.
  • Lung Cancer Research Foundation, Scientific Advisory Board Member, without compensation.
  • Via, Co-Chair for Non-Small Cell Lung Cancer Pathway, receiving honoraria.

Emily Taylor

Ms. Taylor was diagnosed with Stage IV lung cancer in 2012 at age 28, with no known genomic markers. After undergoing chemotherapy, radiation and surgery to remove my entire right lung, pleura, and parts of my diaphragm, pericardium, and mediastinum, and thrilled to have NED (no evidence of disease) for the past 6+ years.

As a young, healthy athlete and never smoker, she is working to change the public perception of who gets lung cancer, so that we can achieve better funding, better research, and better outcomes for patients. She volunteer as a Spokesperson/Patient Advocate for the Go2 Foundation for Lung Cancer (formerly Addario Lung Cancer Foundation and Lung Cancer Alliance), and also serve on the Speakers Bureau for the City of Hope, sharing her story at conferences and fundraising events. She also serves as a member of the American Board of Internal Medicine Medical Oncology Board, and maintains a blog, sharing her progress from diagnosis to present, which connects her with patients all over the world.

In her spare time, she enjoy spending time with her husband and their twin daughters, who were born from the embryos they preserved before starting treatment, and were carried by her dear friend and high school track coach.